1. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High- Risk Acute Lymphoblastic Leukemia 
Samer A. Srour, Denái R. Milton, Asad Bashey, Amado Karduss-Urueta, Monzr M. Al Malki, Rizwan Romee, Scott Solomon, Auayporn Nademanee, Stacey Brown, Michael Slade, Rosendo Perez, Gabriela Rondon, Stephan J. Forman, Richard E. Champlin, Partow Kebriaei, Stefan O. Ciurea 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 2, Pages (February 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
(A) Cumulative incidence (CI) of acute graft-versus-host disease (aGVHD); (B) CI of chronic GVHD (cGVHD); (C) CI of nonrelapse mortality (NRM) and relapse rate; (D) disease-free survival (DFS) and overall survival (OS); (E) DFS by age subgroup in years; (F) DFS by median time from diagnosis to transplantation; (G) DFS by comorbidity score; (H) DFS by presence (yes) or absence (no) of extramedullary disease); and (I) DFS by disease status before transplantation. Abbreviations: CR1, patients in first complete remission; CR2, patients in second complete remission; other, all other patients with primary refractory disease or beyond CR2.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions